";s:4:"text";s:4600:"This is likely due to its potential for better patient outcomes compared to other treatments. The dose and frequency of IVIG treatment assumed in the model was based upon the monograph of the product approved for CIDP treatment in Canada[The cost per gram of IVIG ($59.19) was provided by Canadian Blood Services (personal communication). This unpublished model is a modification of an osteoporosis model published by Goeree The disutility associated with the development of cataracts in the model was assumed to be 0.38 while waiting for surgery and 0.10 after surgery[Background mortality rates by age were based on the most recent Canadian life table data[The initial and maintenance IVIG treatment cost estimates were based on the dose and frequency of IVIG administration and the cost per each IVIG administration. of IVIG usage in patients lacking immunoglobulin has J ALLERGY CLIN IMMUNOL MARCH 2017 S2 PEREZ ET AL. By using this website, you agree to our The population entering the model are assumed to be 54 years of age and weighing 75 kg. The incremental cost per QALY gained of IVIG was estimated to be $687,287. The cost per QALY of IVIG was sensitive to the assumptions regarding frequency and dosing of maintenance IVIG.Based on common willingness to pay thresholds, IVIG would not be perceived as a cost effective treatment for CIDP.Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder that targets the myelin sheaths that wrap the nerves of the peripheral nervous system. The e-mail addresses that you supply to use this service will not be used for any other purpose without your consent.Create a link to share a read only version of this article with your colleagues and friends. Find out about Lean Library Research off-campus without worrying about access issues. The AEs used in the model included fracture, diabetes, glaucoma, cataract and serious infection. Median duration since Ig therapy initiation was 24 months. Differences among these formulations in their manufacturing processes, excipients, pH, and physicochemical properties may be reflected as differences in clinical efficacy, safety, and tolerability. Comparison of Intravenous Immunoglobulin Formulations: Product Formulary, and Cost Considerations Scott M. Mark, PharmD, MS, Med, Mph, MBA Hospital Pharmacy 2011 46 : 9 , 668-676 Six trials were identified that evaluated IVIG and reported response rates[The probabilities of corticosteroid related adverse events were taken from a published cost-effectiveness study comparing corticosteroids with Cox-2 inhibitors for the treatment of rheumatoid arthritis[Background utility values for the model were based upon utilities from a U.K. general population[The incremental gain in utility from IVIG treatment compared to corticosteroid treatment was assumed to be 0.12.